Transaction #2235 · Form 4 · 0001507650-25-000003
Summit Therapeutics Inc. · Stock award · Common Stock
Summit Therapeutics Inc. · Transacted October 21, 2025 · Filed October 23, 2025
What does this filing report?
An SEC Form 4 filing for Summit Therapeutics Inc. records a stock award involving Common Stock on October 21, 2025. The reported quantity was 266,808. The filing date is October 23, 2025. This is one transaction record; amounts are not allocated among any joint reporting owners.
The acquisition category describes how securities were received. It does not by itself establish a cash purchase of common stock. Read the transaction code definitionsand the original filing before interpreting the amounts.
Transaction details
- Company
- Summit Therapeutics Inc.
- Company CIK
- 0001599298
- Security type
- Non-derivative
- Acquisition type
- Stock award · Code A
- Quantity acquired
- 266,808
- Reported price
- 18.74
- Reference value
- 4,999,981.92
- Currency
- Currency not specified
- Ownership
- Indirect
- Holdings after transaction
- 25,724,474
- Ownership description
- By the Mahkam Zanganeh Revocable Trust, with the Reporting Person as Trustee
- SEC acceptance time
- Oct 23, 2025, 4:06 PM EDT
- 10b5-1 indication
- Not indicated
Reference value is reported quantity × reported price. It is not a confirmed cash payment or an estimate of a derivative's economic value. A missing currency is not assumed to be USD.
Reporting owners
- Zanganeh Mahkam ↗
Co-Chief Executive Officer · Director · 10% owner
CIK 0001507650
These are the reporting owners named in the filing. Quantities and amounts are not allocated among co-reporters. Roles reflect this filing, not a current profile.
Company listings
The linked listing is identified separately from other current company listings.
Filing footnotes & remarks
- F1
- Acquired in a private placement transaction pursuant to the terms of a definitive agreement, dated as of October 21, 2025, pursuant to which the Issuer agreed to sell shares of common stock to the Reporting Person and certain other parties at a purchase price of $18.74 per share. The transaction is anticipated to close on or about October 23, 2025.
- F2
- The Reporting Person disclaims beneficial ownership of these securities, except to the extent of her pecuniary interest therein, if any, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 or for any other purpose.
Footnotes are reproduced as plain text from the current source filing. For the full context, read the original SEC filing.
This record was updated Eastern Time. This is the stored record update time, not the transaction date. Report a correction.